---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ESK-001-002"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: ESK-001-002. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 13 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence/esk-001-002"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ESK-001-002

<a id="heading-3.1.12"></a>

## 3.1.12 ESK-001-002

<a id="heading-3.1.12.1"></a>

### 3.1.12.1 Objective

<a id="topic-3.1.12.1-1"></a>

#### Official title in the ClinicalTrials.gov record

> “The Relative Bioavailability of an ESK-001 Tablet Versus Liquid Formulation, and the Effect of Food or Gastric Acid Reduction on the Pharmacokinetics of ESK-001 in Healthy Participants”

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="heading-3.1.12.2"></a>

### 3.1.12.2 Location and Study Date

<a id="topic-3.1.12.2-1"></a>

#### Study start and completion dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2022-03-17”
> “Primary Completion (Actual) 2022-06-30”
> “Study Completion (Actual) 2022-09-20”
> “First Submitted 2022-03-30”
> “First Posted 2022-04-15”

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="topic-3.1.12.2-2"></a>

#### Completion dates estimated at registration, April 2022, superseded in September 2022

> “Primary Completion 2022-04 [Estimated]”
> “Study Completion 2022-04 [Estimated]”

Source: [ClinicalTrials.gov NCT05330858 version 1](https://clinicaltrials.gov/study/NCT05330858?tab=history&a=1)

<a id="topic-3.1.12.2-3"></a>

#### Site in Glendale, California, in the ClinicalTrials.gov record

> “This study has 1 location”
> “Alumis Central Site”

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

| Field | Quoted record |
| --- | --- |
| Location | “Glendale, California, United States, 91206” |

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="topic-3.1.12.2-4"></a>

#### Recruitment and results status in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2023-05-09” |

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="heading-3.1.12.3"></a>

### 3.1.12.3 Study Design

<a id="topic-3.1.12.3-1"></a>

#### Design details in the ClinicalTrials.gov record

> “This is a single-center, in-house, open-label, crossover study in 15 healthy participants.”

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

| Field | Quoted record |
| --- | --- |
| Other study ID numbers | “ESK-001-002” |
| Conditions | “Pharmacokinetics” |
| Primary purpose | “Basic Science” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="topic-3.1.12.3-2"></a>

#### Four-period crossover with an 18-day stay in the clinical research unit in the registered description

> “This is a single-center, in-house, open-label, 4-period, partly randomized crossover study in 15 healthy participants. Each participant will receive a single ESK-001 dose on 4 occasions. Eligible participants will be admitted to the clinical research unit (CRU) on the day prior to the first study drug administration (Day 1, Period 1) and remain in the CRU for 18 days.”

Source: [ClinicalTrials.gov NCT05330858 version 1](https://clinicaltrials.gov/study/NCT05330858?tab=history&a=1)

<a id="heading-3.1.12.4"></a>

### 3.1.12.4 Eligibility Criteria

<a id="topic-3.1.12.4-1"></a>

#### Inclusion and exclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Inclusion: age and health | “Healthy Men and woman age 18-60” |
| Inclusion: consent | “Able to provide written informed consent” |
| Inclusion: pregnancy and lactation | “Females can not be pregnant or lactating” |
| Exclusion: prior exposure | “Prior exposure to ESK-001” |
| Exclusion: malignancy | “History of malignancy within the last 10 years” |
| Exclusion: viral infection | “Positive for HIV, Hepatitis B or C” |
| Exclusion: tuberculosis | “History of tuberculosis” |
| Exclusion: alcohol or drugs | “Positive test for alcohol or drugs” |
| Ages eligible for study | “18 Years to 60 Years (Adult )” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “Yes” |

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="heading-3.1.12.5"></a>

### 3.1.12.5 Treatment

<a id="topic-3.1.12.5-1"></a>

#### Liquid, fasted tablet, fed tablet, and tablet with rabeprazole arms in the ClinicalTrials.gov record

| Arm | Arm description |
| --- | --- |
| “Experimental: ESK-001 Liquid” | “ESK-001 administered as an oral liquid” |
| “Experimental: ESK-001 Tablet Fasted” | “ESK-001 administered as an oral tablet in the fasted state” |
| “Experimental: ESK-001 Tablet Fed” | “ESK-001 administered as an oral tablet in the fed state” |
| “Experimental: ESK-001 and Rabeprazole” | “ESK-001 administered as an oral tablet with rabeprazole” |

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="heading-3.1.12.6"></a>

### 3.1.12.6 Study Outcomes

<a id="heading-3.1.12.6.1"></a>

#### 3.1.12.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

<a id="topic-3.1.12.6.1-1"></a>

##### Primary and secondary outcome measures in the ClinicalTrials.gov record

| Role | Outcome measure | Measure description | Time frame |
| --- | --- | --- | --- |
| Primary | “Assess the PK parameters of ESK-001 via time of maximum plasma concentration (Tmax)” | “Relative bioavailability and food effect assessment via collection and comparison of PK plasma samples between dosing arms” | “18 Days” |
| Primary | “Assess the PK parameters of ESK-001 via maximum plasma concentration (Cmax)” | “Relative bioavailability and food effect assessment via collection and comparison of PK plasma samples between dosing arms” | “18 Days” |
| Primary | “Assess the PK parameters of ESK-001 via area under the concentration time curve (AUC)” | “Relative bioavailability and food effect assessment via collection and comparison of PK plasma samples between dosing arms” | “18 Days” |
| Secondary | “Assess the Incidence of Treatment Emergent Adverse Events of ESK-001” | “Collection and review of incidence of adverse events and serious adverse events” | “25 Days” |

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="heading-3.1.12.7"></a>

### 3.1.12.7 Statistical Analysis Description

<a id="heading-3.1.12.7.1"></a>

#### 3.1.12.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.12.7.1-1"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 14”

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

<a id="topic-3.1.12.7.1-2"></a>

##### Enrollment estimated at registration, April 2022, superseded in May 2023

> “Enrollment 15 [Estimated]”

Source: [ClinicalTrials.gov NCT05330858 version 1](https://clinicaltrials.gov/study/NCT05330858?tab=history&a=1)

<a id="heading-3.1.12.7.2"></a>

#### 3.1.12.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.12.8"></a>

### 3.1.12.8 Results

<a id="heading-3.1.12.8.1"></a>

#### 3.1.12.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.12.8.2"></a>

#### 3.1.12.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.12.8.3"></a>

#### 3.1.12.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.12.8.4"></a>

#### 3.1.12.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.12.8.5"></a>

#### 3.1.12.8.5 Safety Results

No evidence found.

<a id="heading-3.1.12.9"></a>

### 3.1.12.9 Study Limitations

<a id="topic-3.1.12.9-1"></a>

#### Summary

- The relative bioavailability, food effect, and gastric acid reduction comparisons (liquid, tablet fasted, tablet fed, and tablet with rabeprazole) have no posted results, and the report holds no published results; the ClinicalTrials.gov record reads “No Results Posted”.
- The study was a single-center, open-label crossover study; the registered description calls it partly randomized and plans 15 healthy participants, and actual enrollment was 14.
- Each participant received a single dose on 4 occasions, so the comparisons rest on single-dose pharmacokinetics in healthy adults aged 18 to 60 years.

Source: [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858); [ClinicalTrials.gov NCT05330858 version 1](https://clinicaltrials.gov/study/NCT05330858?tab=history&a=1)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
